Galvecta 50mg Tablet is primarily indicated in conditions like Type Il diabetes mellitus.
Galvecta 50mg Tablet is contraindicated in conditions like Hypersensitivity to the drug.
Galvecta 50mg Tablet produces potentially life-threatening effects which include Angioedema. which are responsible for the discontinuation of Galvecta 50mg Tablet therapy.The signs and symptoms that are produced after the acute overdosage of Galvecta 50mg Tablet include Muscle aches, Fever, Swelling of feet and lower legs, Mild paresthesia. The symptomatic adverse reactions produced by Galvecta 50mg Tablet are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Fatigue, Nausea, Asthenia, Hypoglycemia.
Do not use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. not recommended in ESRD on haemodialysis patients. Do not use in patients with hepatic impairment, including patients with pretreatment ALT or AST > 3x ULN. Liver function should be monitored during treatment with Galvecta 50mg Tablet at three-month intervals during the first year and periodically thereafter. Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue it. Following withdrawal of treatment with Galvecta 50mg Tablet and LFT normalisation, treatment with Galvecta 50mg Tablet should not be reinitiated. Monitoring for skin disorders, such as blistering or ulceration, is recommended while keeping with routine care of the diabetic patient.